Literature DB >> 1842209

Monitoring progression in Alzheimer's disease.

D Galasko1, J Corey-Bloom, L J Thal.   

Abstract

OBJECTIVE: To compare several clinical methods of following change in Alzheimer's disease (AD) over time. DATA SOURCES: MEDLINE search (restricted to English language); bibliographies of pertinent articles or books. STUDY SELECTION: Studies included only if aim was to follow a cohort of AD patients; diagnosis of AD used DSM-III-R or NINCDS-ADRDA guidelines; techniques or scales used for serial assessment were well-established in terms of validity and reliability. DATA EXTRACTION: All 3 authors reviewed all studies cited and reached consensus about interpretation.
RESULTS: Global instruments detect long term deterioration in AD and describe distinct through possibly artificial stages. Cognitive screening tests decline at a consistent rate for groups of AD patients but show considerable variability. Scales measuring activities of daily living (ADLs) need further study to determine annual rate of change. Instrumental ADLs decline early in AD and reach a floor before cognitive screening tests. Electrophysiologic or radiographic techniques do not necessarily change over time and are not superior to clinical methods for following AD. Variability in rate of cognitive change and prognosis in AD has not been adequately explained.
CONCLUSIONS: Cognitive screening tests provide useful measures of rate of change in AD for clinical and therapeutic studies. Further studies should take advantage of longer follow-up and more sophisticated statistical techniques to optimize use of these measures.

Entities:  

Mesh:

Year:  1991        PMID: 1842209     DOI: 10.1111/j.1532-5415.1991.tb04463.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  9 in total

1.  Psychotropic drug use in a group of Dutch nursing home patients with dementia: many users, long-term use, but low doses.

Authors:  R T Koopmans; J M van Rossum; H J van den Hoogen; Y A Hekster; M A Willekens-Bogaers; C van Weel
Journal:  Pharm World Sci       Date:  1996-01

2.  Associations of cumulative Pb exposure and longitudinal changes in Mini-Mental Status Exam scores, global cognition and domains of cognition: The VA Normative Aging Study.

Authors:  Zishaan Farooqui; Kelly M Bakulski; Melinda C Power; Marc G Weisskopf; David Sparrow; Avron Spiro; Pantel S Vokonas; Linda H Nie; Howard Hu; Sung Kyun Park
Journal:  Environ Res       Date:  2016-10-19       Impact factor: 6.498

3.  Hallucinations, delusions, and cognitive decline in Alzheimer's disease.

Authors:  R S Wilson; D W Gilley; D A Bennett; L A Beckett; D A Evans
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

4.  Follow-up for Alzheimer patients: European Alzheimer Disease Consortium position paper.

Authors:  F Nourhashémi; M G Olde Rikkert; A Burns; B Winblad; G B Frisoni; J Fitten; B Vellas
Journal:  J Nutr Health Aging       Date:  2010-02       Impact factor: 4.075

5.  Neuropsychological prediction of conversion to dementia from questionable dementia: statistically significant but not yet clinically useful.

Authors:  J Tian; R S Bucks; J Haworth; G Wilcock
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-04       Impact factor: 10.154

6.  Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease.

Authors:  Joseph J Locascio; Hiroaki Fukumoto; Liang Yap; Teodoro Bottiglieri; John H Growdon; Bradley T Hyman; Michael C Irizarry
Journal:  Arch Neurol       Date:  2008-06

Review 7.  Is it really Alzheimer's?

Authors:  M A Spooner
Journal:  Can Fam Physician       Date:  1994-06       Impact factor: 3.275

8.  Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.

Authors:  Carina Wattmo; Asa K Wallin; Lennart Minthon
Journal:  BMC Neurol       Date:  2012-11-05       Impact factor: 2.474

9.  Progression of mild Alzheimer's disease: knowledge and prediction models required for future treatment strategies.

Authors:  Carina Wattmo; Asa K Wallin; Lennart Minthon
Journal:  Alzheimers Res Ther       Date:  2013-10-07       Impact factor: 6.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.